论文部分内容阅读
目的探讨脑卒中急性期临床治疗。方法选取2010年3月至2011年9月诊治符合入选标准脑卒中急性期患者136例分为常规治疗组70例,阿托伐他汀组66例,观察两组临床疗效。结果阿托伐他汀组总有效率90.90%显著优于常规治疗组总有效率68.57%,两组总有效率比较P<0.05差异有统计学意义。结论阿托伐他汀在脑卒中急性期临床治疗中具有降血脂、控制炎症反应、缩短进展达峰时间、减少卒中区扩大、控制临床症状、促进脑卒中康复。
Objective To investigate the clinical treatment of acute stroke. Methods From March 2010 to September 2011, 136 patients with acute stroke who met the inclusion criteria were randomly divided into routine treatment group (n = 70) and atorvastatin group (n = 66). The clinical efficacy of the two groups was observed. Results The total effective rate of atorvastatin group was 90.90%, which was significantly better than that of the conventional treatment group (68.57%). There was significant difference between the two groups in total effective rate (P <0.05). Conclusions Atorvastatin can reduce the blood fat, control the inflammatory reaction, shorten the peak time of progress, reduce the expansion of stroke area, control the clinical symptoms and promote the recovery of stroke in the clinical treatment of acute stroke.